MedulloblastomaMYCMBNCT07694622
Targeting MYC in High-Risk Medulloblastoma
A study testing Tumor tissue collection in people with Medulloblastoma, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by high expression or amplification of the MYC oncogene. Read more about this study
- Who is it for?
- Ages Up to 20 years
- Conditions the study is for
- Medulloblastoma
- What is being tested?
- Tumor tissue collection
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteItaly
- Study dates
- 1 Sep 2026to 1 Sep 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 20 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients with histologically confirmed Group 3 medulloblastoma (G3 MB)
- Age between 0 and 20 years
- Undergoing surgical treatment at the UOC Child Neurosurgery Unit, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome
- Availability of tumor tissue obtained during standard-of-care surgical resection for molecular analyses and/or establishment of patient-derived organoids
- Written informed consent provided by the patient and/or parent/legal guardian (prospective cohort)
- Inclusion of retrospective cases in accordance with applicable Italian privacy regulations (Art. 110-bis)
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site
Fondazione Policlinico Universitario "A. Gemelli", IRCCS - UOC Neurochirurgia Infantile
Rome, Lazio, 00168
GIANPIERO TAMBURRINI, MD, 00393349468776, gianpiero.tamburrini@policlinicogemelli.it
About this study
Official title: Exploiting High MYC Expression as a Potential Vulnerability for Treatment of High-Risk Medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by high expression or amplification of the MYC oncogene. Current treatment strategies are not tailored to this subgroup and are associated with significant long-term toxicities, highlighting the need for more specific therapeutic approaches.
This study aims to characterize biological processes and molecular pathways driven by high MYC expression in high-risk G3 medulloblastoma in order to identify potential therapeutic vulnerabilities. The study will investigate MYC-associated regulation of gene expression and RNA splicing in tumor cells and will define molecular dependencies that may be targeted using candidate or repurposed anticancer agents.
Read more
To achieve this, publicly available genomic datasets will be analyzed, findings will be validated in patient tumor specimens, and patient-derived three-dimensional (3D) tumor models will be established from surgical samples. These models will be used for ex vivo assessment of selected therapeutic strategies in a system that preserves key features of the original tumor.
This translational approach integrates computational analyses, molecular validation, and functional testing in patient-derived models to improve understanding of MYC-associated tumor biology in Group 3 medulloblastoma.
Read the detailed description
Group 3 medulloblastoma (G3 MB) is the most aggressive molecular subgroup of medulloblastoma and is associated with poor prognosis, particularly in tumors characterized by MYC amplification or high MYC expression. Despite multimodal treatment including surgery, chemotherapy, and craniospinal irradiation, overall survival remains limited and survivors frequently experience significant long-term treatment-related toxicities. Given the largely undruggable nature of MYC, identifying MYC-dependent biological processes that can be therapeutically targeted represents an unmet clinical need.
This study investigates molecular mechanisms underlying MYC-driven tumor aggressiveness and aims to identify actionable vulnerabilities in high-risk G3 medulloblastoma. The project integrates retrospective molecular analyses, prospective collection of tumor specimens, transcriptomic data mining, and functional validation using patient-derived models.
Publicly available RNA sequencing datasets will be analyzed to compare tumors with high versus low MYC expression. Differential gene expression and alternative splicing analyses will be integrated with existing experimental datasets from MYC-depleted medulloblastoma models to identify MYC-regulated pathways and molecular processes.
Candidate genes and molecular signatures identified through bioinformatic analyses will be validated in retrospective tumor specimens using quantitative gene expression assays and evaluation of MYC-associated transcriptional and splicing programs.
In parallel, tumor samples collected from prospectively enrolled patients undergoing standard-of-care surgical resection will be used to establish patient-derived three-dimensional (3D) cultures. These models will be characterized histologically and molecularly to assess concordance with the corresponding primary tumors. Only models that retain key histological and genomic features will be used for downstream functional studies.
Patient-derived 3D cultures will be used as ex vivo platforms to evaluate therapeutic strategies targeting MYC-dependent pathways identified in molecular analyses. Selected compounds will be tested individually or in combination using assays measuring cell viability, proliferation, and survival.
This study does not involve investigational medicinal products or medical devices. All clinical procedures, including surgery and tissue collection, are performed according to standard clinical practice, without additional interventions for research purposes.
This translational project integrates computational analyses, molecular validation, and functional testing in patient-derived models to improve understanding of MYC-driven tumor biology in Group 3 medulloblastoma. The molecular insights generated may also be relevant to other pediatric and adult malignancies characterized by MYC dysregulation.
- Conditions
- Medulloblastoma
- Being tested
- Tumor tissue collection
- Keywords
- Medulloblastoma, Group 3 Medulloblastoma, MYC, RNA Splicing, Patient-Derived 3D Cultures, Gene Expression, MYC Amplification, Organoids, Transcriptomics
- Medical subject headings
- Medulloblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tumor tissue collectionProcedure or surgery
Tumor tissue will be collected during standard-of-care surgical resection of medulloblastoma. No additional surgical procedures will be performed for research purposes. Collected tissue will be used for molecular analyses and the establishment of patient-derived three-dimensional (3D) cultures for ex vivo translational research, including characterization of MYC-associated molecular pathways and evaluation of tumor cell responses to selected compounds in preclinical assays.
| Study group | Role | What they receive |
|---|---|---|
| Medulloblastoma tissue collection and ex vivo translational research | Experimental | Participants with medulloblastoma undergoing standard-of-care surgical resection will be enrolled after informed consent. Tumor tissue collected during surgery will be used to generate patient-derived organoids (PDOs) for ex vivo translational research. Analyses will include molecular characterization, transcriptomic profiling, and evaluation of tumor cell responses to selected anticancer compounds in preclinical assays. No investigational drugs or medical devices are administered to participants, and no additional clinical procedures beyond routine care are performed. Receives: Procedure: Tumor tissue collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful establishment of patient-derived organoids (PDOs) from medulloblastoma surgical specimens
Rate of successful generation of patient-derived organoids (PDOs) from freshly resected high-risk Group 3 medulloblastoma surgical specimens. Success will be defined by the ability of tumor samples to generate stable and expandable three-dimensional (3D) cultures in vitro. Established models will be evaluated for histological and molecular concordance with the corresponding parental tumors using standard pathological and genetic analyses.
Measured: Up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Sep 2028 (estimated)
- Study completion1 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MedulloblastomaStudies of the same condition, open and under way.
- More trials run by Fondazione Policlinico Universitario Agostino Gemelli IRCCSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-group translational study involving analysis of tumor specimens collected during standard-of-care surgical procedures. The study includes retrospective and prospective cohorts. No investigational drugs or medical devices are administered. Biological samples are used for molecular analyses and the establishment of patient-derived three-dimensional (3D) models for ex vivo functional studies.
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gianpiero Tamburrini, Principal investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07694622
- Sponsor's protocol ID
- 27529
- Acronym
- MYCMB
- Status last verified
- Jul 2026
- First submitted
- 3 Jul 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploiting High MYC Expression as a Potential Vulnerability for Treatment of High-Risk Medulloblastoma
- ClinicalTrials.gov ID
- NCT07694622
- Acronym / sponsor ID
- MYCMB / 27529
- Conditions
- Medulloblastoma
- Keywords
- Medulloblastoma, Group 3 Medulloblastoma, MYC, RNA Splicing, Patient-Derived 3D Cultures, Gene Expression, MYC Amplification, Organoids
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Sep 2028 (estimated)
- Study completion
- 1 Sep 2029 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by high expression or amplification of the MYC oncogene. Current treatment strategies are not tailored to this subgroup and are associated with significant long-term toxicities, highlighting the need for more specific therapeutic approaches.
This study aims to characterize biological processes and molecular pathways driven by high MYC expression in high-risk G3 medulloblastoma in order to identify potential therapeutic vulnerabilities. The study will investigate MYC-associated regulation of gene expression and RNA splicing in tumor cells and will define molecular dependencies that may be targeted using candidate or repurposed anticancer agents.
To achieve this, publicly available genomic datasets will be analyzed, findings will be validated in patient tumor specimens, and patient-derived three-dimensional (3D) tumor models will be established from surgical samples. These models will be used for ex vivo assessment of selected therapeutic strategies in a system that preserves key features of the original tumor.
This translational approach integrates computational analyses, molecular validation, and functional testing in patient-derived models to improve understanding of MYC-associated tumor biology in Group 3 medulloblastoma.
Detailed description
Group 3 medulloblastoma (G3 MB) is the most aggressive molecular subgroup of medulloblastoma and is associated with poor prognosis, particularly in tumors characterized by MYC amplification or high MYC expression. Despite multimodal treatment including surgery, chemotherapy, and craniospinal irradiation, overall survival remains limited and survivors frequently experience significant long-term treatment-related toxicities. Given the largely undruggable nature of MYC, identifying MYC-dependent biological processes that can be therapeutically targeted represents an unmet clinical need.
This study investigates molecular mechanisms underlying MYC-driven tumor aggressiveness and aims to identify actionable vulnerabilities in high-risk G3 medulloblastoma. The project integrates retrospective molecular analyses, prospective collection of tumor specimens, transcriptomic data mining, and functional validation using patient-derived models.
Publicly available RNA sequencing datasets will be analyzed to compare tumors with high versus low MYC expression. Differential gene expression and alternative splicing analyses will be integrated with existing experimental datasets from MYC-depleted medulloblastoma models to identify MYC-regulated pathways and molecular processes.
Candidate genes and molecular signatures identified through bioinformatic analyses will be validated in retrospective tumor specimens using quantitative gene expression assays and evaluation of MYC-associated transcriptional and splicing programs.
In parallel, tumor samples collected from prospectively enrolled patients undergoing standard-of-care surgical resection will be used to establish patient-derived three-dimensional (3D) cultures. These models will be characterized histologically and molecularly to assess concordance with the corresponding primary tumors. Only models that retain key histological and genomic features will be used for downstream functional studies.
Patient-derived 3D cultures will be used as ex vivo platforms to evaluate therapeutic strategies targeting MYC-dependent pathways identified in molecular analyses. Selected compounds will be tested individually or in combination using assays measuring cell viability, proliferation, and survival.
This study does not involve investigational medicinal products or medical devices. All clinical procedures, including surgery and tissue collection, are performed according to standard clinical practice, without additional interventions for research purposes.
This translational project integrates computational analyses, molecular validation, and functional testing in patient-derived models to improve understanding of MYC-driven tumor biology in Group 3 medulloblastoma. The molecular insights generated may also be relevant to other pediatric and adult malignancies characterized by MYC dysregulation.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-group translational study involving analysis of tumor specimens collected during standard-of-care surgical procedures. The study includes retrospective and prospective cohorts. No investigational drugs or medical devices are administered. Biological samples are used for molecular analyses and the establishment of patient-derived three-dimensional (3D) models for ex vivo functional studies.
| Arm | Type | Receives |
|---|---|---|
| Medulloblastoma tissue collection and ex vivo translational research | Experimental | Procedure: Tumor tissue collectionParticipants with medulloblastoma undergoing standard-of-care surgical resection will be enrolled after informed consent. Tumor tissue collected during surgery will be used to generate patient-derived organoids (PDOs) for ex vivo translational research. Analyses will include molecular characterization, transcriptomic profiling, and evaluation of tumor cell responses to selected anticancer compounds in preclinical assays. No investigational drugs or medical devices are administered to participants, and no additional clinical procedures beyond routine care are performed. |
Who may qualify
- Ages
- Up to 20 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Patients with histologically confirmed Group 3 medulloblastoma (G3 MB)
- Age between 0 and 20 years
- Undergoing surgical treatment at the UOC Child Neurosurgery Unit, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome
- Availability of tumor tissue obtained during standard-of-care surgical resection for molecular analyses and/or establishment of patient-derived organoids
- Written informed consent provided by the patient and/or parent/legal guardian (prospective cohort)
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tumor tissue collectionTumor tissue will be collected during standard-of-care surgical resection of medulloblastoma. No additional surgical procedures will be performed for research purposes. Collected tissue will be used for molecular analyses and the establishment of patient-derived three-dimensional (3D) cultures for ex vivo translational research, including characterization of MYC-associated molecular pathways and evaluation of tumor cell responses to selected compounds in preclinical assays. | Procedure or surgery | Medulloblastoma tissue collection and ex vivo translational research |
Primary outcome
Successful establishment of patient-derived organoids (PDOs) from medulloblastoma surgical specimens
Time frame: Up to 24 months
Rate of successful generation of patient-derived organoids (PDOs) from freshly resected high-risk Group 3 medulloblastoma surgical specimens. Success will be defined by the ability of tumor samples to generate stable and expandable three-dimensional (3D) cultures in vitro. Established models will be evaluated for histological and molecular concordance with the corresponding parental tumors using standard pathological and genetic analyses.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Medulloblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
RecruitingPhase 2
Digoxin Medulloblastoma Study
Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Active, not recruitingPhase 2
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Glioblastoma, Medulloblastoma
RecruitingPhase 1
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Ependymoma, Medulloblastoma
RecruitingPhase 1
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gianpiero Tamburrini principal investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tumor tissue collection in people with Medulloblastoma, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gianpiero Tamburrini (+393349468776, gianpiero.tamburrini@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful establishment of patient-derived organoids (PDOs) from medulloblastoma surgical specimens (time frame: Up to 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.